Chargement en cours...

BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy

Combining immunotherapy with targeted therapy blocking oncogenic BRAF(V600) may result in improved treatments for advanced melanoma. Here, we developed a BRAF(V600E)-driven murine model of melanoma, SM1, which is syngeneic to fully immunocompetent mice. SM1 cells exposed to the BRAF inhibitor vemura...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Koya, Richard C., Mok, Stephen, Otte, Nicholas, Blacketor, Kevin J., Comin-Anduix, Begonya, Tumeh, Paul C., Minasyan, Aspram, Graham, Nicholas A., Graeber, Thomas G., Chodon, Thinle, Ribas, Antoni
Format: Artigo
Langue:Inglês
Publié: 2012
Sujets:
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3422880/
https://ncbi.nlm.nih.gov/pubmed/22693252
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-11-2837
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!